This is a working overview of chain of custody, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-07-18. Anything still debated is marked as such rather than presented as settled.
Identity and purity are usually established with reversed-phase high-performance liquid chromatography for the main peak and with mass spectrometry for the observed molecular mass. Peptide mapping after enzymatic digestion confirms the primary sequence, while amino acid analysis provides a quantitative composition check. Size-exclusion chromatography and ion-exchange chromatography are used to look for aggregates and charge variants. Water content, residual solvents, and counter-ion content are measured separately, since a lyophilised powder is often reported on an as-is basis unless a correction is applied.
Research-grade material circulates through suppliers that differ widely in documentation and testing practice, so a certificate of analysis is a starting point rather than proof of quality. Independent verification typically repeats chromatographic purity and mass confirmation on the received lot, and compares results against a retained reference standard. Regulatory status varies by jurisdiction, and a substance cleared as a medicine is not interchangeable with a research chemical of the same name. Open questions include how closely non-pharmaceutical lots match approved material in impurity profile and in aggregate content.
Identity and purity are established with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry for confirmation of the expected mass. Peptide mapping after enzymatic digestion verifies the primary sequence and detects substitutions. Size-exclusion chromatography quantifies aggregates and fragments, which are the impurities most often tracked for peptides of this size. Residual solvents, counterions, and water content fall under separate tests described in pharmacopeial chapters. Circular dichroism or nuclear magnetic resonance may be used in research settings to probe secondary structure, though such methods are less common in routine release testing.
Peptide active ingredients of this type are typically supplied as lyophilized powder because the dry form resists hydrolysis during transport. The material is hygroscopic, so vials are usually equilibrated to room temperature before opening to avoid condensation on the solid. Repeated freeze-thaw cycles can promote aggregation and are generally avoided by aliquoting stock into single-use portions. Personnel handling the powder work in controlled environments to limit inhalation of fine particles. Written procedures usually specify these steps rather than leaving them to individual judgment.
Long-term storage of the solid generally relies on temperatures at or below minus twenty degrees Celsius, while short-term working stocks may be held refrigerated. Light exposure is limited because photodegradation can alter side chains over extended periods. Solutions prepared for analysis are less stable than the dry powder and are typically used within the same working day. Buffer choice matters, since some aqueous conditions favor deamidation or oxidation at specific residues. Stability data are usually generated under defined accelerated conditions and then extrapolated with stated assumptions.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilised solid, may form a loose cake |
| Solubility class | Soluble in water | Practically insoluble in nonpolar solvents |
| Storage temperature, solid | -20 °C or below | Desiccated and protected from light |
| Storage temperature, liquid | 2-8 °C | Refrigerated, not frozen |
| Typical identity method | LC-MS | Observed mass compared with calculated mass |
Research and analytical settings increasingly require documentation of peptide origin and chain of custody. Certificate of analysis documents typically report purity by chromatographic area, mass confirmation, appearance, and residual solvent or counterion content. Independent verification by an accredited laboratory is common when a material will be used in a regulated study. Open questions remain about how well compendial methods transfer between laboratories, and about which impurity thresholds are meaningful for materials not intended for clinical use.
Peptide-based pharmaceutical products such as tirzepatide require controlled temperature management to preserve structural integrity. Manufacturer labeling generally specifies refrigeration at 2 to 8 degrees Celsius before first use, with protection from light and freezing. Exposure to repeated temperature cycling can promote aggregation or deamidation, which alters the analytical profile even when the visible solution appears unchanged. Once a product is in use, the permitted storage window and temperature range are defined by the specific labeled presentation rather than by general peptide rules.
Development began in the 2010s, when researchers modified a GIP-based scaffold to add GLP-1 activity and then attached the fatty diacid to lengthen its half-life. Clinical evaluation proceeded through large phase 3 programmes in type 2 diabetes and in obesity, and regulators in the United States cleared the compound for type 2 diabetes in 2022 and for chronic weight management in 2023. Several cardiovascular and metabolic outcome studies are still reporting, so the picture of long-term benefit and risk is incomplete. Approvals in other regions followed on different timelines.
Tirzepatide is a synthetic peptide of 39 amino acids that carries a C20 fatty diacid side chain attached through a linker. Its molecular formula is C225H348N48O68, and its molecular weight is about 4813 daltons. The compound belongs to the incretin mimetic class and is administered by subcutaneous injection. The fatty acid chain promotes binding to serum albumin, which slows renal clearance and extends the circulation time of the molecule. It was identified during screening of sequences derived from glucose-dependent insulinotropic polypeptide.
Tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor, making it a dual agonist rather than a selective agent. Engagement of the GLP-1 receptor is linked to glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. The relative contribution of the GIP arm remains an active research question; proposed roles include improved insulin sensitivity and altered adipose tissue handling. Receptor occupancy studies suggest the molecule interacts with both targets at circulating concentrations achieved during therapy.
In addition to oral activity, 17α-alkylation also confers a high potential for hepatotoxicity, and all 17α-alkylated AAS have been associated, albeit uncommonly and only after prolonged use (different estimates between 1 and 17%), with hepatotoxicity. In contrast, testosterone esters have only extremely rarely or never been associated with hepatotoxicity, and other non-17α-alkylated AAS only rarely, although long-term use may reportedly still increase the risk of hepatic changes (but at a much lower rate than 17α-alkylated AAS and reportedly not at replacement dosages). In accordance, D-ring glucuronides of testosterone and DHT have been found to be cholestatic. Aside from prohormones and testosterone undecanoate, almost all orally active AAS are 17α-alkylated. A few AAS that are not 17α-alkylated are orally active. Some examples include the testosterone 17-ethers cloxotestosterone, quinbolone, and silandrone, which are prodrugs (to testosterone, boldenone (Δ1-testosterone), and testosterone, respectively), the DHT 17-ethers mepitiostane, mesabolone, and prostanozol (which are also prodrugs), the 1-methylated DHT derivatives mesterolone and metenolone (although these are relatively weak AAS), and the 19-nortestosterone derivatives dimethandrolone and 11β-MNT, which have improved resistance to first-pass hepatic metabolism due to their 11β-methyl groups (in contrast to them, the related AAS trestolone (7α-methyl-19-nortestosterone) is not orally active). As these AAS are not 17α-alkylated, they show minimal potential for hepatotoxicity.
=== Limitation of the measurement method === Mass spectra alone lack sufficient information to unambiguously identify every molecule. Some molecules produce almost indistinguishable spectra – even more similar than the same molecule measured on two different instruments. Extensive follow-up experiments are required for unambiguous identification. Based thereon, it is impossible to always correctly identify a molecular structure merely from a mass spectrum. Thus, CSI:FingerID as well as other methods for structure database search, cannot guarantee finding the correct molecular structure as first hit. That is why it is important to have the correct structure ranked very high from an extensive list of candidates and to assess the confidence in the top hit.
==== India ==== India has the world's second-largest number of think tanks. Most are based in New Delhi, and a few are government-sponsored. There are few think tanks that promote environmentally responsible and climate resilient ideas like Centre for Science and Environment, Centre for Policy Research and World Resources Institute. There are other prominent think tanks like Observer Research Foundation, Tillotoma Foundation, and Centre for Civil Society. In Mumbai, Strategic Foresight Group is a global think tank that works on issues such as water diplomacy, peace and conflict and foresight (futures studies). Think tanks with a development focus include those like the National Centre for Cold-chain Development ('NCCD'), which serve to bring an inclusive policy change by supporting the Planning Commission and related government bodies with industry-specific inputs – in this case, set up at the behest of the government to direct cold chain development. Some think tanks have a fixed set of focus areas and they work towards finding out policy solutions to social problems in the respective areas. Initiatives such as National e-Governance Plan (to automate administrative processes) and National Knowledge Network (NKN) (for data and resource sharing amongst education and research institutions), if implemented properly, should help improve the quality of work done by think tanks. Some notable think tanks in India include:
In February 2009, the guerrilla group released 6 hostages as a humanitarian gesture. In March, they released Swedish hostage Erik Roland Larsson. In April 2009, the Colombian armed forces launched "Strategic Leap", an offensive in border areas where the FARC's forces still had a strong military presence, especially in Arauca, near the Venezuelan border. In November 2009, nine Colombian soldiers were killed when their post was attacked by FARC guerrillas in a southwestern part of the country. On December 22, 2009, FARC rebels raided the home of Provincial governor Luis Francisco Cuéllar, killing one police officer and wounding two. Cuéllar was found dead the following day.
=== Female genitalia === Many female spiders possess sac-like structures where sperm from the male spider is stored; however, females of the P. phalangioides species do not have these receptaculum seminis. Instead, the posterior wall of uterus externus, or genital cavity, serves as the site of sperm storage. The females have two accessory glands located in the dorsal part of the uterus externus. These glands release a secretion into the uterus externus which functions as a matrix to hold the male spermatozoa and seminal fluid in place upon copulation. These accessory glands are composed of multiple glandular units, they themselves consisting of two secretory and envelope cells each. The inner and outer envelope cells surround the secretory cells and serve to create a cuticular ductule or canal that runs from the secretory cells to the two pore plates located on the uterus externus. These pore plates are the exit sites for the aforementioned glandular secretion into the uterus externus.
Sources: en.wikipedia.org
Niacin is incorporated into multi-vitamin and sold as a single-ingredient dietary supplement. The latter can be immediate or slow release. Nicotinamide is used to treat niacin deficiency and for supplementation because it does not cause the flushing adverse reaction seen with nicotinic acid. Nicotinamide may be toxic to the liver at doses exceeding 3 g/day for adults. One form of dietary supplement sold in the US is inositol hexanicotinate (IHN), also called inositol nicotinate. This is inositol that has been esterified with niacin on all six of inositol's alcohol groups. IHN is usually sold as "flush-free" or "no-flush" niacin in units of 250, 500, or 1000 mg/tablets or capsules. In the US, it is sold as an over-the-counter formulation, and often is marketed and labeled as niacin, thus misleading consumers into thinking they are getting an active form of the medication. While this form of niacin does not cause the flushing associated with the immediate-release products, there is not enough evidence to recommend IHN to treat hyperlipidemia.
Agarose is a preferred matrix for work with proteins and nucleic acids as it has a broad range of physical, chemical and thermal stability, and its lower degree of chemical complexity also makes it less likely to interact with biomolecules. Agarose is most commonly used as the medium for analytical scale electrophoretic separation in agarose gel electrophoresis. Gels made from purified agarose have a relatively large pore size, making them useful for separation of large molecules, such as proteins and protein complexes >200 kilodaltons, as well as DNA fragments >100 basepairs. Agarose is also used widely for a number of other applications, for example immunodiffusion and immunoelectrophoresis, as the agarose fibers can function as anchor for immunocomplexes.
Some have active camouflage that changes with need. Distraction eye, many fish have spot on the tail to fool potential predators and prey; both are not sure which is the front, the direction of travel. Gills appear in unrelated fish, some amphibians, some crustacean, aquatic insects and some mollusk, like freshwater snails, squid, octopus.
Sherman (1930–2008), 12 US patents John Sherwood (died 2020), British physical chemist Nevil Vincent Sidgwick (1873–1952), English theoretical chemist, known for work in valency Osamu Shimomura (1928–2018), 2008 Nobel Prize in Chemistry Hideki Shirakawa (1936–2026), 2000 Nobel Prize in Chemistry Alexander Shulgin (1925–2014), pioneer researcher in Psychopharmacology and Entheogens Salimuzzaman Siddiqui (1897–1994), Pakistani chemist, pioneer in natural products chemistry Oktay Sinanoglu (1935–2015), Turkish chemist Joseph H. Simons (1897–1983), U.S. chemist, discoverer of fluorocarbons, used in gaseous diffusion of Uranium for Manhattan project Jens Christian Skou (1918–2018), 1997 Nobel Prize in Chemistry Richard Smalley (1943–2005), 1996 Nobel Prize in Chemistry Michael Smith (1932–2000), 1993 Nobel Prize in Chemistry Ascanio Sobrero (1812–1888), Italian chemist, discoverer of nitroglycerin Frederick Soddy (1877–1956), British chemist, 1921 Nobel Prize in Chemistry Susan Solomon (born 1956), American atmospheric chemist Ernest Solvay (1838–1922), Belgian chemist and industrialist S.P.L. Sørensen (1868–1939), Danish chemist Gabor A.
Raynaud syndrome, also known as Raynaud's phenomenon, is a medical condition in which the spasm of small arteries causes episodes of reduced blood flow to end arterioles. Typically the disease affects the fingers, and, less commonly, the toes, though it rarely also affects the nose, ears, nipples, or lips. The episodes classically result in the affected part turning white and then blue. Often, numbness or pain occurs. As blood flow returns, the area turns red and burns. The episodes typically last minutes but can last several hours. The condition is named after the physician Auguste Gabriel Maurice Raynaud, who first described it in his doctoral thesis in 1862. Episodes are typically triggered by cold or emotional stress. Primary Raynaud's is idiopathic (spontaneous and of unknown cause) and not correlated with another disease. Secondary Raynaud's is diagnosed given the presence of an underlying condition and typically is associated with an older age of onset. In comparison to primary Raynaud's, episodes of secondary Raynaud's are more likely to be painful and asymmetric and to progress to digital ulcerations. Secondary Raynaud's can be due to a connective-tissue disorder such as scleroderma or lupus, injuries to the hands, prolonged vibration, smoking, thyroid problems, and certain medications, such as birth control pills and stimulants. Diagnosis is typically based on the symptoms. The primary treatment is avoiding the cold. Other measures include the discontinuation of nicotine or other stimulant use.
Sources: en.wikipedia.org
It is normally kept frozen, desiccated, and away from light, with brief warming to room temperature before opening to limit condensation. Repeated freeze-thaw cycles are avoided because they stress the peptide. Once in solution, the material is held cold and used promptly.
Mass spectrometry gives the observed molecular mass, which is compared with the calculated value for the expected sequence. Reversed-phase chromatography shows retention behaviour and main peak purity. Peptide mapping adds sequence-level confirmation when the question requires it.
Typical entries include appearance, chromatographic purity as area percent, observed mass, water or residual solvent content, and the analytical methods used. The document reflects the lot tested and the laboratory that performed the work. It does not by itself establish that the delivered vial matches the tested lot.
Water promotes hydrolysis and deamidation, so removing it slows degradation during transport and storage. The dry solid is also less prone to microbial growth than a solution. Reconstitution is therefore performed close to the point of use.